Home
Cancer Biomarkers
KRAS Mutation
Details
70 Trials
3 Therapies
Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol)
Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome
First line
,
+1 more
context
First line
,
+1 more
context
bevacizumab + onvansertib + FOLFIRI regimen
FDA Fast Track
2020-05-28